

ImmunOs has pipeline of novel agents in development

18 February 2020 | News

ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services



ProBioGen AG has announced that ImmunOs Therapeutics AG has signed a Manufacturing Services Agreement for their novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing.

ImmunOs has a pipeline of novel agents in development.

Dr. Wieland Wolf, CEO of ProBioGen: “We are pleased about this confidence in our expertise. It is our goal enabling ImmunOs to start clinical trials with this promising molecule in a timely manner. We are very passionate to develop a cell line and respective robust processes based on our innovative technologies to deliver their product with highest quality.”

No further details were disclosed.